MINERALYS THERAPEUTICS, INC. Payments to Acquire Held-to-maturity Securities
MINERALYS THERAPEUTICS, INC. (MLYS) reported Payments to Acquire Held-to-maturity Securities of $657.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. payments to acquire held-to-maturity securities for the quarter ending 2026-06-30 was $310.22M, a 163.16% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. payments to acquire held-to-maturity securities for the quarter ending 2026-03-31 was $347.44M, a 171.70% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. payments to acquire held-to-maturity securities for the quarter ending 2025-12-31 was $268.47M, a 319.95% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. payments to acquire held-to-maturity securities for the quarter ending 2025-09-30 was $300.51M, a 410.56% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. payments to acquire held-to-maturity securities for fiscal 2025 was $814.74M, a 118.17% increase from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. payments to acquire held-to-maturity securities for fiscal 2024 was $373.44M, a 7.32% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. payments to acquire held-to-maturity securities for fiscal 2023 was $347.97M, a 384.92% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. payments to acquire held-to-maturity securities for fiscal 2022 was $71.76M.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $310.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $657.66M 10-Q · filed 2026-08-11 | $926.14M derived: sum of 3 quarters · filed 2026-08-11 | $1.23B derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $347.44M 10-Q · filed 2026-05-06 | $615.92M derived: sum of 2 quarters · filed 2026-05-06 | $916.42M derived: sum of 3 quarters · filed 2026-05-06 | $1.03B derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $268.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $568.98M derived: sum of 2 quarters · filed 2026-03-12 | $686.86M derived: sum of 3 quarters · filed 2026-08-11 | $814.74M 10-K · filed 2026-03-12 |
| 2025-09-30 | $300.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $418.39M derived: sum of 2 quarters · filed 2026-08-11 | $546.26M 10-Q · filed 2025-11-10 | $610.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $117.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $245.76M 10-Q · filed 2026-08-11 | $309.69M derived: sum of 3 quarters · filed 2026-08-11 | $368.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $127.88M 10-Q · filed 2026-05-06 | $191.81M derived: sum of 2 quarters · filed 2026-05-06 | $250.66M derived: sum of 3 quarters · filed 2026-05-06 | $377.93M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $63.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $122.79M derived: sum of 2 quarters · filed 2026-03-12 | $250.05M derived: sum of 3 quarters · filed 2026-03-12 | $373.44M 10-K · filed 2026-03-12 |
| 2024-09-30 | $58.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $186.12M derived: sum of 2 quarters · filed 2025-11-10 | $309.51M 10-Q · filed 2025-11-10 | $382.60M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $127.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $250.66M 10-Q · filed 2025-08-12 | $323.75M derived: sum of 3 quarters · filed 2025-08-12 | $379.74M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $123.39M 10-Q · filed 2025-05-12 | $196.48M derived: sum of 2 quarters · filed 2025-05-12 | $252.47M derived: sum of 3 quarters · filed 2025-05-12 | $308.61M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $73.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $129.08M derived: sum of 2 quarters · filed 2025-02-12 | $185.22M derived: sum of 3 quarters · filed 2025-02-12 | $347.97M 10-K · filed 2025-02-12 |
| 2023-09-30 | $55.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $112.13M derived: sum of 2 quarters · filed 2024-11-12 | $274.88M 10-Q · filed 2024-11-12 | $274.88M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $56.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $218.89M 10-Q · filed 2024-08-13 | $218.89M derived: sum of 3 quarters · filed 2024-08-13 | $290.65M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $162.75M 10-Q · filed 2024-05-09 | $162.75M derived: sum of 2 quarters · filed 2024-05-09 | $234.51M derived: sum of 3 quarters · filed 2024-05-09 | $234.51M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $71.76M derived: sum of 2 quarters · filed 2024-03-21 | $71.76M derived: sum of 3 quarters · filed 2024-03-21 | $71.76M 10-K · filed 2024-03-21 |
| 2022-09-30 | $71.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $71.76M derived: sum of 2 quarters · filed 2023-11-07 | $71.76M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |